Skip to content
The Chinese Cancer Fix episode artwork

May 10, 2026 13 min

The Chinese Cancer Fix

from The Morning Brief Hosted by The Economic Times

A quiet revolution is underway in Indian oncology. Chinese-origin cancer drugs, brought to India through a growing number of pharma partnerships, are dramatically cutting the cost of immunotherapy — making treatment accessible to patients who previously had no options. Doctors are prescribing them, patients are responding well, and Indian companies — from Glenmark to Dr Reddy’s to Intas — are signing billion-dollar deals to expand access further. Western immunotherapy can cost up to five lakh rupees per session. Chinese-origin alternatives are bringing that down to fifty thousand. This episode explores how the India-China pharma axis is reshaping who gets treated, and how.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

The Chinese Cancer Fix

0:00 13:13

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of The Morning Brief?

This episode is 13 minutes long.

When was this The Morning Brief episode published?

This episode was published on May 10, 2026.

Can I download this The Morning Brief episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.